Fragile X mental retardation protein and synaptic plasticity

Michael S Sidorov, Benjamin D Auerbach and Mark F Bear*

Abstract
Loss of the translational repressor FMRP causes Fragile X syndrome. In healthy neurons, FMRP modulates the local translation of numerous synaptic proteins. Synthesis of these proteins is required for the maintenance and regulation of long-lasting changes in synaptic strength. In this role as a translational inhibitor, FMRP exerts profound effects on synaptic plasticity.

Keywords: FMRP, Protein synthesis, Synaptic plasticity, Long-term depression, Long-term potentiation, Metabotropic glutamate receptor, Fragile X

Background
The long-term maintenance of many forms of synaptic plasticity requires the synthesis of new proteins. While the role of experience-dependent somatic gene transcription in long-term memory has been well studied [1], many mRNAs are trafficked to dendrites suggesting an additional role for local synaptic control of protein synthesis [2]. Indeed, activity-dependent translation of pre-existing dendritic mRNA at the synapse is necessary for the expression of multiple forms of synaptic plasticity [3-5]. Fragile X mental retardation protein (FMRP) influences this synaptic plasticity by functioning as a key regulator of mRNA translation [6-10].

FMRP was first characterized in the context of Fragile X syndrome. The FMR1 gene is silenced in Fragile X (FX), and the consequent loss of FMRP leads to the symptoms of the disorder, often including intellectual disability and autism. In the Fmr1 KO mouse model [11], loss of FMRP results in increased levels of protein synthesis [9,12]. The downstream consequences of this increase are believed to be at the core of FX pathophysiology [13-15]. Rapid progress has been made characterizing how loss of FMRP influences synaptic function and plasticity, and this knowledge has led to several strategies to correct the disorder that have been validated in animals and are now being tested in humans [16-19].

Here we briefly review the evidence, mostly from the Fmr1 KO mouse, suggesting a role for FMRP in synaptic plasticity. Although the distinction is not always clear-cut, it is conceptually important to separate disruptions of synaptic plasticity that are consequences of altered brain development from those disruptions of synaptic plasticity that cause altered brain function in the Fmr1 KO. While both are important for understanding disease pathophysiology, only the latter is relevant to the question of how FMRP contributes to synaptic plasticity in the wild-type brain.

FMRP regulates translation
FMRP is an RNA-binding protein and a repressor of translation which is well-conserved from mouse to human. FMRP associates with mRNAs through one of three RNA-binding domains [20,21], in some cases in conjunction with adaptor proteins [22,23]. There is evidence that FMRP can repress translation both by blocking initiation and elongation [15,24,25]. A point mutation in one FMRP/mRNA binding domain is sufficient to recapitulate plasticity phenotypes seen in the Fmr1 KO mouse [26] and in at least one case FX in a human patient [27]. Thus it is likely that FMRP regulates plasticity mainly in its role as a repressor of translation.

FMRP is regulated by posttranslational modifications. Phosphorylated FMRP stalls ribosomal translocation and inhibits translation, whereas dephosphorylation of FMRP upregulates translation [28-30]. Bidirectional regulation of FMRP phosphorylation by the S6 kinase and protein
phosphatase 2A (PP2A) in response to activity provide a potential link between synaptic stimulation and local translation [24].

**FMRP is well-positioned to regulate synaptic plasticity**

FMRP is well-positioned to be a key regulator of synaptic plasticity for three main reasons. First, the protein is found in dendritic spines [31-34], important postsynaptic sites of plasticity induction and maintenance. Secondly, FMRP regulates dendritic mRNA translation [16,17], which is required for multiple forms of plasticity [35]. Finally, FMRP itself is dynamically regulated by activity; experience and synaptic activation can trigger its local translation and rapid degradation, in addition to the posttranslational regulation mentioned above. Multiple experimental manipulations associated with synaptic plasticity have been shown to increase FMRP levels, including exposure to an enriched environment, a complex learning task, and pharmacological activation of group 1 metabotropic glutamate receptors (mGluRs) [31,36-38]. Importantly, FMRP is synthesized rapidly, on the same time scale (10–30 minutes) as induction of stable synaptic plasticity [37]. In hippocampal cultures, activity- and mGluR-dependent increases in dendritic FMRP may result from increased trafficking of existing FMRP, rather than de novo FMRP synthesis [33,39,40]. Either way, FMRP is an ideal candidate to be involved in regulating synaptic plasticity because of its rapid, transient rise in dendrites following well-characterized plasticity induction paradigms, as well as its role as an inhibitor of translation.

**FMRP regulates mGluR-LTD via protein synthesis**

Long-term potentiation (LTP) and long-term depression (LTD) are well-characterized forms of synaptic plasticity associated with learning and memory. These persistent changes in synaptic strength can be induced by a variety of manipulations and their expression mechanisms are diverse. Different induction protocols rely on different mechanisms for maintenance, including the requirement for protein synthesis. A particularly compelling example of a form of plasticity requiring local translation is metabotropic glutamate receptor-dependent LTD (mGluR-LTD) in the CA1 region of the hippocampus. Activation of group 1 mGluRs (mGluR1 and 5), either with paired-pulse low-frequency synaptic stimulation (PP-LFS) [4] or with the selective agonist (S)-3,5-dihydroxyphenylglycine (DHPG) [41,43], results in a persistent decrease in synaptic strength that is mechanistically distinct from classical NMDA receptor (NMDAR)-dependent LTD [41,44]. It is important to note that there are several mechanisms downstream of mGluR activation that can depress synaptic transmission, and these can be differentially expressed depending on the induction protocol, age, rearing history, and species (e.g., [44-48]). However, under appropriate experimental conditions the maintenance of mGluR-LTD requires rapid protein synthesis within minutes of induction [4,49]. This protein synthesis is likely to be synaptic, as mGluR-LTD can still be induced if the dendritic layer is physically severed from the cell body layer [4]. mGluR-LTD is expressed, in part, by the removal of AMPA receptors from synapses, which also requires rapid de novo translation [50]. The new protein synthesis may be instructive rather than merely permissive for synaptic plasticity since activation of group 1 mGluRs rapidly stimulates protein synthesis in hippocampal slices [12], dendrites and synaptoneurosomes [51,52].

**Fmr1 knockout mice show enhanced hippocampal mGluR-LTD**

While the effects of protein synthesis inhibition on mGluR-LTD can be seen within minutes, most forms of synaptic plasticity do not require de novo synthesis until several hours after induction. This is best characterized by late phase LTP (L-LTP), a persistent form of potentiation lasting at least 4 hours. The late maintenance phase of L-LTP requires protein synthesis but initial induction does not [59,60]. Due to FMRP’s conjectured role in translation regulation, L-LTP was one of the first forms of plasticity studied in the Fmr1 KO mouse [49,56]. These results, combined with what is known about FMRP function, suggest that FMRP acts to inhibit the synthesis of proteins required for mGluR-LTD. In the absence of FMRP, these “LTD proteins” are already available or over-expressed in dendrites resulting in enhanced magnitude and protein synthesis-independent persistence of this form of plasticity (Figure 1A) [13]. Conversely, postnatal overexpression of FMRP reduces the magnitude of mGluR-LTD in both wildtype and Fmr1 KO neurons [49] and restores its protein synthesis dependence [57]. Moreover, reducing mGluR5 signaling in Fmr1 KO mice restores both protein synthesis rates and LTD magnitude in the hippocampus to wildtype levels [53,58], suggesting that mGluR5 and FMRP act in functional opposition to maintain an optimal level of synaptic protein synthesis throughout development and into adulthood (Figure 1A).

**L-LTP appears normal in Fmr1 KO mice**

While the effects of protein synthesis inhibition on mGluR-LTD can be seen within minutes, most forms of synaptic plasticity do not require de novo synthesis until several hours after induction. This is best characterized by late phase LTP (L-LTP), a persistent form of potentiation lasting at least 4 hours. The late maintenance phase of L-LTP requires protein synthesis but initial induction does not [59,60]. Due to FMRP’s conjectured role in translation regulation, L-LTP was one of the first forms of plasticity studied in the Fmr1 KO mouse [61]. Interestingly, no difference has been found in the magnitude of L-LTP in the Fmr1 KO [61,62]. The fact that removal of FMRP affects protein synthesis-dependent LTD but not LTP suggests that FMRP may specifically regulate the translation of proteins required for the expression of
However, while the magnitude of L-LTP is unchanged, it is possible that L-LTP is qualitatively different in its requirement for new protein synthesis when FMRP is absent, as is the case for mGluR-LTD (and LTP priming, see below). Therefore, it will be important to test the protein synthesis-dependency of L-LTP in Fmr1 KO mice to show that FMRP truly does not play a role in regulating the persistence of LTP.

Alternatively, FMRP may be required for the regulation of local but not somatic translation in the context of L-LTP (Figure 1C). L-LTP is traditionally induced by multiple trains of high frequency tetanus or theta burst stimulation, protocols that rely on cell-wide transcription and translation [63-65]. L-LTP was characterized in the Fmr1 KO mouse using these classical paradigms [61,62]. However, using a less intense induction protocol

---

Table 1 Fragile X mouse synaptic plasticity phenotypes

| Category | Region | Fragile X Mouse Phenotype | Age | References |
|----------|--------|---------------------------|-----|------------|
| mGluR LTD | hippocampus | enhanced | P25-30 | Huber et al., 2002; Hou et al., 2006; Bhattacharya et al., 2012; Michalson et al., 2012 |
| mGluR LTD | hippocampus | does not require new protein synthesis | 4-12 wk | Nosyreva and Huber, 2006; Hou et al., 2006; Zang et al., 2009** |
| mGluR LTD | hippocampus | enhanced and not PS-dependent | P35-42 | Iliff et al., 2012 |
| mGluR LTD | cerebellum | enhanced | 3-7 wk | Koekkoek et al., 2005 |
| mGluR LTD | hippocampus | enhanced and does not require new protein synthesis | 3-7 wk | Volk et al., J Neurosci, 2007 |
| LTP | hippocampus | NONE | 20-26 wk; 8-10 wk; 3-12 month | Godfraind et al., 1996; Li et al., 2002; Larson et al., 2005 |
| L-LTP | hippocampus | NONE | 5-7 wk; 2-4 month | Paradee et al., 1999; Zhang et al., J 2009 |
| LTP | hippocampus | deficient | 2 wk; 6-8 wk | Hu et al., 2008; Shang et al., 2009 |
| LTP | hippocampus | deficient with weak stimulus; normal with strong stimulus | 2-3 month | Lauterborn et al., 2007 |
| LTP | hippocampus | enhanced B-adrenergic-facilitated heterosynaptic LTP (PS-dependent) | 3-4 month | Connor et al., 2011 |
| LTP | hippocampus | does not require new protein synthesis (mGluR-dependent) | 6-10 wk | Auerbach and Bear, 2010 |
| LTP | anterior cingulate ctx | deficient | 6-8 wk | Zhao et al., 2005; Xu et al., 2012 |
| LTP | anterior cingulate ctx | impaired facilitation of LTP by 5-HT2AR agonist | 6-8 wk | Xu et al., 2012 |
| LTP | somatosensory, temporal ctx | deficient | 8-10 wk; 3 month | Li et al., 2002; Hayashi et al., 2007 |
| LTP | somatosensory ctx | delayed window for plasticity | P3-10 | Harlow et al., 2010 |
| LTP | visual ctx | deficient (mGluR-dependent) | P13-25 | Wilson and Cox, 2007 |
| LTP | anterior piriform ctx | deficient in aged mice; normal in 3-6 mo mice | 6-18 month | Larson et al., 2005 |
| LTP | amygdala | impaired (mGluR-dependent) | 6-8 wk; 3.5-6 mo | Zhao et al., 2005; Suvrathan et al., 2010 |
| STD-LTP | somatosensory ctx | deficient with weak stimulus | P10-18 | Desai et al., 2006 |
| STD-LTP | prefrontal ctx | deficient with weak stimulus; normal with strong stimulus | P14-23 | Meredith et al., 2007 |
| homeostasis | hippocampus | deficient translation-dependent scaling | P6-7 slice culture | Soden and Chen, 2010 |
| homeostasis | hippocampus | normal transcription-dependent scaling | P6-7 slice culture | Soden and Chen, 2010 |
| experience-dependent | visual ctx (in vivo) | altered ocular dominance plasticity | LTD | Dolen et al., 2007 |
| experience-dependent | somatosensory ctx | deficient experience-dependent plasticity (induced by whisker trimming) | LTD | Bureau et al., 2008 |

**LEGEND:** Fragile X mouse models have multiple altered forms of synaptic plasticity across multiple brain regions. The majority of phenotypes were assessed in the Fmr1 KO mouse which lacks FMRP. *Assessed using a CGG knock-in mouse which models FX premutation. **Assessed using an FMRP point mutant mouse with disrupted FMRP-mRNA binding.
results in L-LTP that is maintained specifically by local dendritic translation [5,66]. This form of L-LTP, similar to mGluR-LTD, is sensitive to inhibitors of translation but not transcription, and can be maintained in isolated dendrites. It will be interesting to determine if this locally expressed form of L-LTP is regulated by FMRP.

**FMRP regulates LTP priming**

While the role of FMRP in L-LTP is unclear, FMRP is known to be involved in LTP in other contexts. In particular, FMRP is involved in regulation of an mGluR-dependent form of metaplasticity that sets the threshold for LTP. Originally described in rats [67], weak activation of group 1 mGluRs, in itself insufficient for LTD induction, facilitates the subsequent induction of LTP (“LTP priming”). As with mGluR-LTD, this facilitation requires translation but not transcription [68]. This prompted the examination of the role of FMRP in LTP priming [69]. mGluR-dependent priming of LTP is of comparable magnitude in WT and Fmr1 KO mice; however, while LTP priming requires acute stimulation of protein synthesis in WT mice, it is no longer protein synthesis-dependent in the Fmr1 KO. Thus, while mGluR-LTD and LTP priming are qualitatively different functional consequences of Gp1
mGluR-stimulated protein synthesis in the hippocampus, both processes are altered by the removal of FMRP (Figure 1D). These results suggest that the mRNA under translational control of FMRP may code for proteins required for bidirectional changes in synaptic strength. Thus, the proteins regulated by FMRP should be conceptualized as plasticity gatekeepers rather than solely “LTD proteins.”

The induction threshold for LTP and STD-LTP is raised in Fmr1 KO mice

In Fmr1 KO hippocampal slices, LTP induction is deficient with a weak 5 theta burst protocol but is normal with a strong 10 theta burst protocol (Figure 2A) [70]. In addition, FMRP modulates the induction threshold for spike-timing dependent long-term potentiation (STD-LTP). This form of Hebbian plasticity is induced by temporally staggered presynaptic and postsynaptic activity within a very short window [71,72]. In somatosensory and prefrontal cortices, STD-LTP is deficient in Fmr1 KO neurons [73,74]. However, if the postsynaptic stimulus strength is increased from a single spike to a burst of five spikes, STD-LTP does occur in KO neurons (Figure 2A) [74]. Therefore FMRP is not required for expression of STD-LTP, but the threshold is raised in its absence. A possible mechanism for ongoing regulation of LTP thresholds by FMRP is discussed later in this review.

FMRP and other translation-dependent forms of plasticity

In addition to its role in translation-dependent forms of Hebbian plasticity, FMRP can also modulate some forms of homeostatic plasticity. Synaptic scaling is a form of homeostatic plasticity that acts to keep the strength of synapses within a functional range in response to extreme changes in activity. Broadly, a decrease in activity leads to a subsequent cell-wide increase in synaptic strength (“scaling up”) and an increase in activity leads to a decrement in synaptic strength (“scaling down”) [75]. Two types of scaling up have been described in hippocampal slice culture: one that requires transcription [76] and one that requires local translation [77]. Interestingly, only the translation-dependent form of synaptic scaling is deficient in neurons lacking FMRP. Postsynaptic viral expression of FMRP corrects deficient translation-dependent scaling up in Fmr1 KO neurons [78]. Scaling down of synapses in response to high levels of activity (following prolonged blockade of inhibition) has also been observed [79] and requires mGluR5 activation [80,81]. However, the role of FMRP and local protein synthesis in scaling down has not been directly examined.

Figure 2: FMRP and Kv4.2 regulate the threshold for inducing synaptic potentiation. (A) FMRP sets the threshold for LTP and STD-LTP. Fmr1 KO mice have deficient hippocampal LTP and cortical STD-LTP only with a “weak” induction protocol. (B) Kv4.2 is a dendritic A-type K+ channel that attenuates action potential backpropagation (bAP) and dendritic excitability. (C) Inhibition of Kv4.2 restores LTP following a weak induction protocol in Fmr1 KO mice.
While the role of FMRP has been best characterized in mGluR-dependent forms of plasticity, it is not specific to these receptors. Removal of FMRP occludes TrkB-mediated increases in protein synthesis [12] and alters other forms of G protein-coupled receptor (GPCR)-dependent LTD and LTP [82,83]. The common thread between these processes is their reliance on local dendritic translation. Indeed, evidence suggests that FMRP may specifically be important for the regulation of local rather than somatic translation (Figure 1C), as removal of FMRP affects translation but not transcription-dependent forms of Hebbian and homeostatic plasticity.

**FMRP and translation-independent plasticity**

While many forms of translation-dependent synaptic plasticity are abnormal in Fmr1 KO mice, other forms of hippocampal plasticity, including NMDAR-dependent LTD and early-phase LTP, are normal [8,61,69,84,85]. These observations suggest that FMRP regulates plasticity mainly in its role as a regulator of translation. However, removal of FMRP has also been shown to affect some forms of synaptic plasticity that do not require de novo translation, such as early-phase LTP in other brain areas, including the cortex and amygdala [61,85-89]. Some of these effects could be explained by FMRP modulation of protein synthesis-dependent plasticity thresholds; however it seems likely that many represent end-stage consequences of altered synaptic development in the Fmr1 KO.

A case in point is altered LTP in the amygdala. A substantial deficit in basal transmission was reported at the same synapses that showed impaired LTP [88]. Reduced synaptic connectivity might have caused the defective LTP, and might have arisen as a consequence of increased FMRP-dependent protein synthesis during the development of amygdala circuitry.

**Candidate plasticity gating proteins regulated by FMRP**

In order to determine how FMRP regulates synaptic plasticity, we must identify the synaptic proteins whose translation is regulated by FMRP. FMRP has a wide variety of targets - it has been shown to selectively bind approximately 4% of the mRNA in the mammalian brain [90]. Recently, over 800 mRNA binding targets of FMRP were identified using a novel high throughput cross-linking immunoprecipitation (HITS-CLIP) assay [10]. These targets include genes coding for pre- and postsynaptically expressed proteins: 27% of pre-synaptic protein mRNAs (90 genes) and 23% of postsynaptic protein mRNAs (257 genes) are FMRP targets [10]. More specifically, the HITS-CLIP study found that 31% of mRNAs coding for proteins in the NMDAR complex (58 genes), 62% in the mGluR5 complex (32 genes), and 33% in the AMPAR complex (3 genes) are FMRP targets. These three receptor complexes are important for the induction and maintenance of synaptic plasticity, suggesting that FMRP likely acts broadly as a translational regulator rather than solely regulating one or two “plasticity proteins.”

The finding that many FMRP targets encode presynaptic proteins is interesting and illuminating. In the mature nervous system the evidence for local protein synthesis in axons or axon terminals is still sparse; however during early axon development and synapse formation local protein synthesis is believed to play an important role in pathway and target selection [91,92]. Thus, the absence of FMRP regulation of protein synthesis during early development very likely alters synaptic connectivity well before the onset of experience-dependent postnatal plasticity. In addition, outside the CNS, local control of translation in sensory afferent terminals plays a role in nociceptive sensitization and neuropathic pain [93]. FMRP is localized to these terminals and Fmr1 KO mice show altered nociceptive sensitization [94]. These results suggest that in the spinal cord, presynaptic FMRP may inhibit local translation and can regulate pain plasticity even into adulthood.

We have discussed two major categories of plasticity defects in Fmr1 KO mice: (1) forms of plasticity requiring FMRP/local translation for their maintenance (mGluR-LTD) and (2) forms of plasticity where FMRP regulates their induction threshold (STD-LTP). We will discuss a few proteins in both categories that are likely involved given their regulation by FMRP and their known roles in plasticity maintenance and threshold-setting in wild-type synapses. These “candidate proteins” are meant to serve as exemplars of how FMRP might regulate synaptic plasticity.

**Plasticity maintenance proteins: MAP1B, Arc, and STEP**

Recent work has identified proteins whose translation is regulated by FMRP and are involved in mGluR-LTD, including microtubule-associated protein 1B (MAP1B) and activity-regulated cytoskeleton-associated protein (Arc) [17,18]. MAP1B is required for mGluR-dependent AMPA receptor endocytosis [95], the mechanism by which mGluR-LTD is expressed. FMRP associates with MAP1B mRNA and represses its translation [90,96-98], and Fmr1 KO mice show increased hippocampal MAP1B expression [49]. However, there may be mouse strain and region-specific variations in how FMRP regulates MAP1B translation. For example, in the cerebellum and hippocampus of FVB mice, FMRP may positively regulate MAP1B expression [99].

Arc is involved in AMPAR endocytosis [100] and is upregulated in dendrites following mGluR activation [101,102] and behavior [103]. Arc is required for hippocampal mGluR-LTD and L-LTP, which are both protein synthesis-dependent, and Arc+/- mice have multiple learning deficits [101,102,104]. FMRP binds Arc mRNA
and suppresses its translation. As a result, Arc expression is increased in Fmr1 KO dendrites [98,105,106]. Since (a) mGluR-LTD is increased in Fmr1 KO mice, (b) Arc is increased in Fmr1 KO dendrites, and (c) Arc is required for mGluR-LTD, it seems likely that FMRP regulates mGluR-LTD via Arc. This hypothesis was tested directly using Fmr1/Arc double knockout mice which show deficient (rather than exaggerated) mGluR-LTD [8,102]. This finding suggests that increased Arc expression may partially account for the enhanced mGluR-LTD seen in Fmr1 KO mice.

Mechanistically, dephosphorylation of FMRP by the phosphatase PP2A is required for rapid mGluR-mediated increases in Arc protein. However in Fmr1 KO neurons, Arc levels are basally increased, occluding a further effect of DHPG treatment. Acute viral reintroduction of FMRP into Fmr1 KO neurons normalizes dendritic Arc levels and restores rapid mGluR-mediated Arc synthesis. This provides further evidence that the acute loss of FMRP, rather than developmental abnormality, underlies synaptic plasticity phenotypes in the Fmr1 knockout mouse. Regulation of translation.

In addition to MAP1B and Arc, numerous other candidate LTD proteins have been identified in the Fmr1 KO mouse. One interesting example is striatal-enriched protein tyrosine phosphatase (STEP). Translation of STEP is increased during mGluR-LTD [107,108], and STEP mRNA binds to FMRP [10]. Genetic reduction of STEP corrects increased during mGluR-LTD [107,108], and STEP mRNA binds to FMRP [10]. Genetic reduction of STEP corrects increased LTD seen in Fmr1 KO mice.

FMRP, synaptic plasticity and learning

Long-lasting synaptic potentiation and depression have long been considered potential neural correlates of learning and memory. In conjunction with FMRP’s role in synaptic plasticity in multiple brain areas, FMRP is also important for a wide range of behavioral learning tasks in mice. Fmr1 KO mice show deficient amygdalar trace fear memory [87], cerebellar learning [54], inhibitory avoidance learning [58], and have difficulties with a prefrontal cognitive learning task [128]. Drosophila mutants lacking FMRP also have impaired long-term memory [129]. Overall, learning and memory deficits in the Fmr1 KO mouse are a likely behavioral consequence of abnormal synaptic plasticity.

Conclusions

FMRP participates in the regulation of numerous forms of synaptic plasticity, including mGluR-LTD, LTP priming, and synaptic scaling. It seems that FMRP is particularly important for synaptic plasticity that requires local translation and FMRP is a well-established regulator of local translation. The current evidence suggests that FMRP plays an essential role in regulating the synaptic expression of proteins required for bidirectional changes in synaptic strength (Figure 1). It is likely that FMRP controls the expression of proteins not only acutely required for expression of synaptic plasticity, but also proteins that regulate the threshold for plasticity induction.
(Figure 2). Therefore FMRP’s role in synaptic plasticity is two-fold: it regulates the translation of proteins that directly participate in the induction and expression of plasticity as well as proteins that can indirectly modulate the properties of plasticity.

A key goal in the Fragile X field is to identify which proteins are regulated by FMRP and how increases or decreases in these proteins may account for phenotypes of the disorder. Determining the proteins that are regulated by FMRP (and altered in FX) will also lead to a better understanding of the neuronal processes that are essential for synaptic plasticity and learning/memory. The HTS-CLIP screen has identified hundreds of candidate genes and a significant number of these are putatively involved in synaptic plasticity. It is unlikely that there is one global “plasticity protein” - multiple proteins likely regulate different processes in parallel. Mapping which proteins are essential for which processes is the important next step for understanding the role of FMRP in the pathological and non-pathological brain.

The Fmr1 KO mouse provides a model for assessing the role of FMRP in synaptic plasticity - but on their own, studies in Fmr1 KO mice leave open the possibility that developmental rather than acute changes result in altered synaptic plasticity. In multiple contexts, acute manipulations of FMRP suggest that FMRP does actively regulate synaptic plasticity as a regulator of translation. There is ample evidence that FMRP can directly impact synaptic plasticity through its control of protein synthesis. Future work that allows for better temporal and spatial control of FMRP expression will help dissect the role of FMRP in development from its acute effects on synaptic plasticity.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
All authors drafted, read, and approved the manuscript.

Received: 9 January 2013 Accepted: 25 March 2013 Published: 8 April 2013

References
1. Kandel ER: The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001, 294:1030–1038.
2. Steward O, Levy WB: Preferential localization of polyribosomes under the base of dendritic spines in granule cells of the dentate gyrus. J Neurosci 1982, 2:284–291.
3. Kang H, Schuman EM: A requirement for local protein synthesis in neurotrophin-induced hippocampal synaptic plasticity. Science 1996, 273:1402–1406.
4. Huber KM, Kayser MS, Bear MF: Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science 2000, 288:1254–1257.
5. Huang YY, Kandel ER: Theta frequency stimulation induces a local form of late phase LTP in the CA1 region of the hippocampus. Learn Mem 2005, 12:587–593.
6. Laggerbauer B, Oستareck D, Keidel EM, Oстareck-Lederer A, Fischer U: Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum Mol Genet 2001, 10:329–338.
7. Li Z, Zhang Y, Ku L, Wilkinson KD, Warren ST, Feng Y: The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res 2001, 29:2276–2283.
8. Huber KM, Gallagher SM, Warren ST, Bear MF: Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 2002, 99:7746–7750.
9. Qin M, Kang J, Burlin TV, Jiang C, Smith CB: Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the Fmr1 null mouse. J Neurosci 2005, 25:5087–5095.
10. Damell JC, Van Driessche SJ, Zhang C, Hung KY, Mele A, Fraser CE, Stone EF, Chen C, Fak JJ, Chi SW, et al: FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011, 146:247–261.
11. Consortium TD-BFX: Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 1994, 78:23–33.
12. Osterweil EK, Krueger DD, Reinhold K, Bear MF: Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci 2010, 30:15616–15627.
13. Bear MF, Huber KM, Warren ST: The mGluR theory of fragile X mental retardation. Trends Neurosci 2004, 27:373–379.
14. Brattchathinga A, Kaphzan H, Alvarez-Dieppa AC, Murphy JP, Pierre P, Klann E: Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 2012, 76:335–337.
15. Blakat AL, Dolen G, Bear MF: The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci 2012, 35:417–443.
16. Garber K, Smith KT, Reines D, Warren ST: Transcription, translation and fragile X. Curr Opin Genet Dev 2006, 16:270–275.
17. Bassell GJ, Warren ST: Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 2008, 60:201–214.
18. Pfeiffer BE, Huber KM: The state of synapses in fragile X syndrome. Neuroscientist 2009, 15:549–567.
19. Krueger DD, Bear MF: Toward fulfillng the promise of molecular medicine in fragile X syndrome. Annu Rev Med 2011, 62:411–430.
20. Ashley CT Jr, Wilkinson KD, Reines D, Warren ST: FMR1 protein: conserved RNP family domains and selective RNA binding. Science 1993, 262:563–566.
21. Sioni H, Somi MC, Nussbaum RL, Dreyfuss G: The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 1993, 74:291–208.
22. Napolitano MC, Boyl PP, Leutner U, Zalla F, De Rubels S, Di Marino D, Mohr E, Massimi M, Falcioni M, et al: The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell 2008, 134:1042–1054.
23. El Fatimy R, Tremblay S, Dury AY, Solomon S, De Koninck P, Schrader JW, Kriajidian EW: Fragile X mental retardation protein interacts with the RNA-binding protein Caprin1 in neuronal RiboNucleoProtein complexes (corrected). PLoS One 2012, 7:e99338.
24. Santoro MR, Bray SM, Warren ST: Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu Rev Pathol 2012, 7:219–245.
25. Boggi C, Greenough WT: From mRNP trafficking to spine dysmophogenesis: the roots of fragile X syndrome. Nat Rev Neurosci 2005, 6:376–387.
26. Zang JB, Nosyrev ED, Spencer CM, Volk LI, Musumuru K, Zhang R, Stone EF, Yuva-Paylor LA, Huber KM, Paylor R, et al: A mouse model of the human Fragile X syndrome I304N mutation. Proc Natl Acad Sci USA 2009, 106:5087–5092.
27. Beuller K, Verkerk AJ, Reynolds E, Vits L, Hendrickz J, Van Roy B, Van den Bos F, de Graaff E, Oostra BA, Willems PJ: A point mutation in the FMR1 gene associated with fragile X mental retardation. Nat Genet 1993, 3:31–35.
28. Coffey RJ, Jr, Williamson AJ, Adkins CM, Gray MC, Page TL, Brodie K: In vivo neuronal function of the fragile X mental retardation protein is regulated by phosphorylation. Hum Mol Genet 2012, 21:900–915.
29. Muddaththury RS, Nalavadi VC, Gross C, Yao X, Xing L, Laur O, Warren ST, Bassell GJ: Reversible inhibition of PSD-95 mRNA translation by mR1-125a, FMRP phosphorylation, and mGluR signaling. Mol Cell 2011, 42:673–688.
30. Ceman S, O'Donnell WT, Reed M, Patton S, Pohl J, Warren ST: Phosphorylation influences the translation state of FMRP-associated polyribosomes. Hum Mol Genet 2003, 12:3295–3305.
31. Weller III, Irlin SA, Kleinsotava AY, Spencer CM, Braeldon AD, Miyashiro K, Cornely TA, Patel B, Eberwine J, Greenough WT: Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci USA 1997, 94:5395–5400.
32. Feng Y, Absher D, Eberhart DE, Brown V, Malter HE, Warren ST: FMRP associates with polyribosomes as an mRNP, and the I304N mutation of
severe fragile X syndrome abolishes this association. Mol Cell Neurosci 1997, 10:119–108.

33. Antar LN, Afroz R, Dicenten JB, Carroll RC, Bassell GJ: Metabotropic glutamate receptor activation regulates fragile X mental retardation protein and mGluR1 mRNA localization differentially in dendrites and at synapses. J Neurosci 2004, 24:5258–5265.

34. Ferrai F, Mercaldo V, Piccoli G, Sala C, Cattaneo S, Acsel T, Bagni C: The fragile X mental retardation protein-RNP granules show an mGlur-dependent localization in the post-synaptic spines. Mol Cell Neurosci 2007, 34:343–354.

35. Sutton MA, Schuman EM: Dendritc protein synthesis, synaptic plasticity, and memory. Cell 2006, 127:49–58.

36. Irwin SA, Swain RA, Christmon CA, Chakravarti A, Weiler IJ, Greenough WT: Evidence for altered Fragile-X mental retardation protein expression in response to behavioral stimulation. Neurobiol Learn Mem 2000, 74:873–93.

37. Gabel LA, Won S, Kawa H, McKinney M, Tartakoff AM, Fallon JR: Visual experience regulates transient expression and dendritic localization of fragile X mental retardation protein. J Neurosci 2004, 24:10579–10583.

38. Todd PK, Milner JS, Mack JJ: Whisker stimulation-dependent translation of FMN1 in the barrel cortex requires activation of type 1 metabotropic glutamate receptors. Brain Res Mol Brain Res 2003, 110:267–278.

39. Antar LN, Dicenten JB, Plociniak M, Afroz R, Bassell GJ: Localization of FMN1-associated mRNA granules and requirement of microtubules for activity-dependent trafficking in hippocampal neurons. Genes Brain Behav 2005, 4:350–361.

40. Dicenten JB, Swanger SA, Antar LN, Singer RH, Bassell GJ: A direct role for FMN1 in activity-dependent dendritic mRNA transport links filopodial spine morphogenesis to fragile X syndrome. Dev Cell 2008, 16:926–939.

41. Palmer MJ, Irving AJ, Seabrook GR, Jane DE, Collingridge GL: Properties and mechanisms of LTP. Nat Rev Neurosci 2008, 9(15):1032–1046.

42. Huber KM, Bear MF: Metabotropic glutamate receptor activation regulates fragile X mental retardation protein replacement restores hippocampal synaptic function in a model of fragile X syndrome. J Neurosci 2008, 28:13289–13295.

43. Zieger Z, Kumar A, Bodnianathan K, Feller J, Foster TC, Bloom DC: Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome. Gene Ther 2009, 16:112–1129.

44. Dolenz G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattaraj S, Bear MF: Correction of fragile X syndrome in mice. Neuron 2007, 56:565–562.

45. Stanton PK, Saney JM: Blockade of long-term potentiation in rat hippocampal CA1 region by inhibitors of protein synthesis. J Neurosci 1984, 4:3080–3088.

46. Frey U, Krug M, Reymann KG, Matthies H: Anisomycin, an inhibitor of protein synthesis, blocks late phases of LTP phenomena in the hippocampal CA1 region in vitro. Brain Res 1988, 452:65–65.

47. Oliet SH, Malenka RC, Nicoll RA: Developmental switch in synaptic mechanisms of p38 mitogen-activated protein kinase and protein tyrosine depression. J Neurophysiol 2003, 35:1099–1109.

48. Nosyreva ED, Huber KM: Long-term potentiation and depression in area CA1 of rat hippocampus. Soc Neurosci Abstr 1998, 22.

49. Huber KM, Roder JC, Bear MF: Anisomycin, an inhibitor of protein synthesis, blocks late phases of LTP phenomena in the hippocampal CA1 region in vitro. Brain Res 1998, 452:65–65.

50. Snyder EM, Philpot BD, Huber KM, Dong X, Fallon JR, Bear MF: Anisomycin, an inhibitor of protein synthesis, blocks late phases of LTP phenomena in the hippocampal CA1 region in vitro. Brain Res 1998, 452:65–65.

51. Job C, Eberwine J: Altered hippocampal synaptic plasticity in the FMR1 gene family knockout mouse models. J Neurophysiol 2009, 101:2599–2608.

52. Abraham WC, Williams JM: Properties and mechanisms of LTP maintenance. Neuroscience 2003, 96:453–474.

53. Krug M, Blossner B, Ott T: Anisomycin blocks the late phase of long-term potentiation in the dentate gyrus of freely moving rats. Brain Res Bull 1984, 13:39–42.

54. Irwin SA, Swain RA, Christmon CA, Chakravarti A, Weiler IJ, Greenough WT: Evidence for altered Fragile-X mental retardation protein expression in response to behavioral stimulation. Neurobiol Learn Mem 2000, 74:873–93.

55. Nakamoto M, Naradavi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST: Fragile X mental retardation protein deficiency leads to excessive mGlur5-dependent internalization of AMPA receptors. Proc Natl Acad Sci USA 2007, 104:15537–15542.

56. Nosyreva ED, Huber KM: Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J Neurophysiol 2005, 93:3291–3295.

57. Zeier Z, Kumar A, Bodnianathan K, Feller J, Foster TC, Bloom DC: Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome. Gene Ther 2009, 16:112–1129.

58. Ito M: The self-tuning neuron: synaptic scaling of excitatory synapses. Cell 2008, 135:422–435.

59. Ikeda K, Sun Q, Turrigiano GG: Rapid synaptic scaling induced by changes in postsynaptic firing. J Neurosci 2008, 28:10685–10694.

60. Krueger A, Kovalnik M, Voss M, Abler F, Kastberger G: Anisomycin, an inhibitor of protein synthesis, blocks late phases of LTP phenomena in the hippocampal CA1 region in vitro. Brain Res 1998, 452:65–65.

61. Lauterborn JC, Rex CS, Kramer E, Chen LY, Pandarajan V, Lynch G, Gall CM: Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J Neurosci 2007, 27:10685–10694.

62. Krueger A, Kovalnik M, Voss M, Abler F, Kastberger G: Anisomycin, an inhibitor of protein synthesis, blocks late phases of LTP phenomena in the hippocampal CA1 region in vitro. Brain Res 1998, 452:65–65.

63. Lauterborn JC, Rex CS, Kramer E, Chen LY, Pandarajan V, Lynch G, Gall CM: Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J Neurosci 2007, 27:10685–10694.

64. Lauterborn JC, Rex CS, Kramer E, Chen LY, Pandarajan V, Lynch G, Gall CM: Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J Neurosci 2007, 27:10685–10694.

65. Lauterborn JC, Rex CS, Kramer E, Chen LY, Pandarajan V, Lynch G, Gall CM: Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J Neurosci 2007, 27:10685–10694.

66. Lauterborn JC, Rex CS, Kramer E, Chen LY, Pandarajan V, Lynch G, Gall CM: Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J Neurosci 2007, 27:10685–10694.
Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, Jin X, Price TJ, Rashid MH, Millecamps M, Sanoja R, Entrena JM, Cervero F: Akins MR, Berk-Rauch HE, Fallon JR: Li J, Pelletier MR, Perez Velazquez JL, Carlen PL: Connor SA, Hoeffer CA, Klann E, Nguyen PV: Hu JH, Park JM, Park S, Xiao B, Dehoff MH, Kim S, Hayashi T, Schwarz MK, Sidorov et al. Molecular Brain

Results Probl Cell Differ

Neurosci Bull

Cell

Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 2005, 13(58):735–792.

Suvarthan A, Hoffker CA, Wong H, Klann E, Chattarji S: Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc Natl Acad Sci USA 2010, 107:15911–15916.

Wilson BM, Cox CL: Absence of metabotropic glutamate receptor-mediated plasticity in the neocortex of fragile X mice. Proc Natl Acad Sci USA 2007, 104:24544–24549.

Brown V, Jin P, Ceman S, Darnell JC, O’Donnell WT, Tenenbaum SA, Jin X, Fung W, Wilkinson KD, Keene JD, et al: Microarray characterization of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 2005, 13(58):735–792.

Jung H, Yoon BC, Holt CE: Axonal mRNA localization and local protein synthesis in the nervous system: assembling, maintenance and repair. Nat Rev Neurosci 2012, 13(308):324.

Akins MR, Berk-Rauch HE, Fallon JR: Presynaptic stepping: output of the postsynaptic shadow. Front Neural Circuits 2009, 3:17.

Price TJ, Melemedjian OK: Multiple Gq-coupled receptors associated with fragile X mental retardation protein deficiency. Mol Cell Neurosci 2002, 19:138–151.

Haayashi ML, Rao BS, So JS, Choi HS, Dohan BM, Choi JH, Chattarji S, Tonegawa S: Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proc Natl Acad Sci USA 2007, 104:11489–11494.

Zhao MQ, Toyoda H, Ko SW, Ding HK, Wu LL, Zhuo M: Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome. J Neurosci 2005, 25(38):7395–7392.

79. Turrisiano GG, Leslie KR, Desai NS, Rutherford LC, Nelson SB: Activity-dependent scaling of quantal amplitude in neocortical neurons. Nature 1998, 391:892–896.

80. Hu JH, Park JM, Park S, Xiao B, Dehoff MH, Kim S, Hayashi T, Schwarz MK, Huganir RL, Seeburg PH, et al: Homeostatic scaling requires group I mGluR activation mediated by Homer1a. Neuroto 2010, 68:1128–1142.

81. Zhong X, Li H, Chang Q: mGlu2/3 phosphorylation is required for modulating synaptic scaling through mGluR5. J Neurosci 2012, 32:12841–12847.

82. Volk LJ, Pfeiffer BE, Gibson JR, Huber KM: Multiple Gq-coupled receptors converge on a common protein synthesis-dependent long-term depression that is affected in fragile X syndrome mental retardation. J Neurosci 2007, 27:11624–11634.

83. Connor SA, Hoffker CA, Klann E, Nguyen PV: Fragile X mental retardation protein regulates heterosynaptic plasticity in the hippocampus. Learn Mem 2011, 18:207–220.

84. Godfraind JM, Reyniers E, De Boule K, D’Hooge R, De Deyn PP, Bakker CE, Sheperd JD, Bear MF: New views of Arc, a master regulator of synaptic plasticity. Nat Neurosci 2011, 14:729–784.

85. Li J, Pelletier MR, Perez Velazquez JL, Carlen PL: mGluR activation mediated by Homer1a.

86. Niere F, Willerson JR, Huber KM: Evidence for a fragile X mental retardation protein-mediated translational switch in metabotropic glutamate receptor-triggered Arc translation and long-term depression. J Neurosci 2012, 32:5924–5936.

87. Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, Oostra B, Bagni C: The fragile X syndrome protein FMRP associates with BC1 RNA and the spinal sensory system.

88. Godfraind JM, Reyniers E, De Boule K, D’Hooge R, De Deyn PP, Bakker CE, Sheperd JD, Bear MF: New views of Arc, a master regulator of synaptic plasticity. Nat Neurosci 2011, 14:729–784.

89. Price TJ, Melemedjian OK: Multiple Gq-coupled receptors associated with fragile X mental retardation protein deficiency. Mol Cell Neurosci 2002, 19:138–151.

90. Lu R, Wang H, Liang Z, Ku L, O’Donnell WT, Li W, Warren ST, Feng Y: The fragile X protein controls microtubule-associated protein 1B translation in the brain of Fmr1 knockout mice. Neurobiol Bull 2007, 23:203–208.

91. Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, Oostra B, Bagni C: The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell 2003, 112:317–327.

92. Wei ZX, Yi YH, Sun WW, Wang R, Su T, Bai YJ, Liao WP: Expression changes of microtubule-associated protein 1B in the brain of fmr1 knockout mice. Neurobiol Bull 2007, 23:203–208.

93. Chowdhury S, Shepherd JD, Okuno H, Lyford G, Petralia RS, Plasth N, Kuhl D, Huganir RL, Worley PF: Arc/Arg3.1 interacts with the endocytic machinery to regulate AMPA receptor trafficking. Neuroen 2006, 52:445–459.

94. Goebel-Goody SM, Baum M, Paspalas CD, Fernandez SM, Canty NC, Kurup P, Lombroso PJ: Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STeP) in neuropsychiatric disorders. Pharmacol Rev 2012, 64:685–687.

95. Niere F, Willerson JR, Huber KM: Evidence for a fragile X mental retardation protein-mediated translational switch in metabotropic glutamate receptor-triggered Arc translation and long-term depression. J Neurosci 2012, 32:5924–5936.

96. Iaconoja A, Rozhdestvensky TS, Dolzhanskaya N, Tourneur B, Schutt J, Brosius J, Denman RB, Khandjian EW, Kindler S, Tiedge H: On BC1 RNA and the fragile X mental retardation protein. Proc Natl Acad Sci USA 2008, 105:734–739.

97. Zhang Y, Veniklanamani DV, Gladding CM, Sprouse BE, Miller CA, Collingridge GL, Lombroso PJ: The fragile X syndrome protein controls microtubule-associated protein 1B translation of Arc/Arg3.1 selectively mediates mGluR-dependent LTD through persistent increases in AMPAR endocytosis rate. Neuron 2008, 59:94–97.

98. Park S, Park JM, Kim S, Kim JA, Shepherd JD, Smith-Hicks CL, Chowdhury S, Kaufmann W, Kuhl D, Ryzanov AG, et al: Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc/Arg3.1 essential for mGluR-LTD. Neuro 2008, 59:70–83.

99. Plath N, Ohana O, Dammermann B, Errington ML, Schmitz D, Gross C, Mao X, Engelsberg A, Mahlke C, Weld H, et al: Arc/Arg3.1 is essential for the consolidation of synaptic plasticity and memories. Neuro 2006, 52:347–344.

100. Wei ZX, Yi YH, Sun WW, Wang R, Su T, Bai YJ, Liao WP: Evidence for a fragile X mental retardation protein-mediated translational switch in metabotropic glutamate receptor-triggered Arc translation and long-term depression. J Neurosci 2012, 32:5924–5936.
122. Zhang Y, Brown MR, Hyland C, Chen Y, Kronengold J, Fleming MR, Kohn AB, Moroz LL, Kaczmarek LK: Regulation of neuronal excitability by interaction of fragile x mental retardation protein with slack potassium channels. *J Neurosci* 2012, 32:15318–15327.

123. Chen X, Yuan LL, Zhao C, Bimbaum SG, Frick A, Jung WE, Schwarz TL, Sweatt JD, Johnston D: Deletion of Kv4.2 gene eliminates dendritic A-type K+ current and enhances induction of long-term potentiation in hippocampal CA1 pyramidal neurons. *J Neurosci* 2006, 26:12143–12151.

124. Hoffman DA, Magee JC, Colbert CM, Johnston D: K+ channel regulation of signal propagation in dendrites of hippocampal pyramidal neurons. *Nature* 1997, 387:869–875.

125. Watanabe S, Hoffman DA, Migliore M, Johnston D: Dendritic K+ channels contribute to spike-timing dependent long-term potentiation in hippocampal pyramidal neurons. *Proc Natl Acad Sci USA* 2002, 99:8366–8371.

126. Jung SC, Kim J, Hoffman DA: Rapid, bidirectional remodeling of synaptic NMDA receptor subunit composition by A-type K+ channel activity in hippocampal CA1 pyramidal neurons. *Neuron* 2008, 60:657–671.

127. Chuang SC, Zhao W, Bauchwitz R, Yan Q, Bianchi R, Wong RK: Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. *J Neurosci* 2005, 25:8048–8055.

128. Krueger DD, Osterweil EK, Chen SP, Tye LD, Bear MF: Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome. *Proc Natl Acad Sci USA* 2011, 108:2587–2592.

129. Bolduc FV, Bell K, Cox H, Brodie KS, Tully T: Excess protein synthesis in Drosophila fragile X mutants impairs long-term memory. *Nat Neurosci* 2008, 11:1143–1145.

doi:10.1186/1756-6606-6-15
Cite this article as: Sidorov et al: Fragile X mental retardation protein and synaptic plasticity. *Molecular Brain* 2013 6:15.